wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q57652734-656A44B5-F3F5-49E2-BAAE-BF6839DCA364
Q57652734-656A44B5-F3F5-49E2-BAAE-BF6839DCA364
BestRank
Statement
http://www.wikidata.org/entity/statement/Q57652734-656A44B5-F3F5-49E2-BAAE-BF6839DCA364
Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors
P2860
Q57652734-656A44B5-F3F5-49E2-BAAE-BF6839DCA364
BestRank
Statement
http://www.wikidata.org/entity/statement/Q57652734-656A44B5-F3F5-49E2-BAAE-BF6839DCA364
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8f16ceef764afa0cb729f327ba85168f105012a2
P2860
The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.